Abstract:Background: Processes that drive Alzheimer's disease pathogenesis have long been considered to occur within the central nervous system, yet recent studies have bolstered the possibility that changes in the periphery may be relevant to the disease process. Accumulating evidence has suggested that proteins changing in the blood may be reliable indicators of disease within the brain. Recent advances in geroscience have identified potential mechanisms of blood-brain communication that modulate brain function in ways that could be harnessed for therapy. While blood-borne proteins associated with either youth or old age have been targeted to restore function to the aged brain, it remains unclear whether other dysfunctional systemic states can be exploited for similar benefits. Here we investigate whether APOE allelic variation or presence of brain amyloid are associated with distinct proteomic changes within the systemic environment and what molecular processes are associated with these changes. Methods: Using the SOMAscan assay, we measured 1,305 plasma proteins from 53 homozygous APOE3 and APOE4 subjects (mean age = 68 years; minimum = 54 years) who exhibited no cognitive impairment, some of whom can be categorized as harboring cerebral amyloid based on cerebrospinal fluid A{beta}42 measurements. Using the Dream R package for linear mixed effects modeling, we investigated possible contributions of either the APOE-{epsilon}4 allele or amyloid positivity to changes in the plasma proteome. Ontology-based pathway and module trait correlation analyses were performed to understand disrupted pathways that vary based on APOE genotype or amyloid positivity. Results: We found that expression of the APOE-{epsilon}4 allele produced distinct changes in the composition of the plasma proteome. Using both pathway enrichment analysis and weighted gene co-expression network analysis, we found that plasma proteins associated with APOE4 expression were linked to pathways related to atherosclerosis, lipid transport, the extracellular matrix, and synaptogenesis signaling. Independent of APOE4, we found that cognitively normal, amyloid-positive subjects exhibit distinct plasma proteome signatures associated with pathways previously linked to AD pathology, relative to amyloid-negative controls. Harboring brain amyloid was associated with plasma proteomic changes linked to dysfunction in blood-brain barrier and other neural cell types. Our results indicate that changes in the plasma proteome are related to possession of AD risk alleles, as well as the presence of amyloid pathology in subjects prior to the onset of symptoms. This work highlights the possibility that pathways in the systemic environment in certain risk contexts may be plausible targets to explore for modulating disease.

Abstract 13280: Proteomic Indicators of Cardiovascular Health Relate to Brain Volume and Dementia Risk

Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life

Associations of plasma proteomics and age-related outcomes with brain age in a diverse cohort

Cardiovascular Risk Burden in Relation to Dementia and Brain Structural and Metabolic Imaging Markers

A Proteomics-Based Approach for Prediction of Different Cardiovascular Diseases and Dementia

Plasma proteome-wide analysis of cerebral small vessel disease identifies novel biomarkers and disease pathways

Abstract 13245: Cardiovascular Risk Burden in Relation to Dementia and Brain Structural Imaging Markers: A Study from UK Biobank

Proteomic Analyses Reveal Plasma EFEMP1 and CXCL12 As Biomarkers and Determinants of Neurodegeneration.

Is an MRI-derived anatomical measure of dementia risk also a measure of brain aging?

Plasma Proteomic Biomarkers in Alzheimer's Disease and Cardiovascular Disease: A Longitudinal Study

Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk

Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline

Plasma proteomic biomarkers and the association between poor cardiovascular health and incident dementia: The UK Biobank study

Identification of circulating proteins associated with general cognitive function among middle-aged and older adults

Healthy lifestyles, plasma proteomic profile and long-term risk of dementia

Proteomic changes in the human cerebrovasculature in Alzheimer's disease and related tauopathies linked to peripheral biomarkers in plasma and cerebrospinal fluid

Inflammatory protein associations with brain MRI measures: Framingham Offspring Cohort

Cerebral Microbleeds, Cerebral Amyloid Angiopathy, and Their Relationships to Quantitative Markers of Neurodegeneration

APOE genotype or presence of brain amyloid alters the plasma proteome in cognitively normal, elderly subjects

The circulating proteome and brain health: Mendelian randomisation and cross-sectional analyses

Plasma Proteomics of Genetic Brain Arteriosclerosis and Dementia Syndrome Identifies Signatures of Fibrosis, Angiogenesis, and Metabolic Alterations